Mónica Rodríguez Valiente1, Francisco J Nicolás2, Ana M García-Hernández3, Cristina Fuente Mora3, Miguel Blanquer3, Patricio J Alcaraz4, Sonia Almansa4, Guadalupe Ruiz Merino5, Ma Dolores López Lucas3, María C Algueró3, Carmen L Insausti3, Antonio Piñero4, José M Moraleda3, Gregorio Castellanos4. 1. Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain; and Department of General Surgery, Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain. 2. Molecular Oncology and TGFß, Research Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). 3. Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain. 4. Department of General Surgery, Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain. 5. FFIS de la Región de Murcia, Support Research Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
Abstract
OBJECTIVE: The amniotic membrane (AM) is a tissue with low immunogenity and high therapeutic potential due to its anti-inflammatory, anti-fibrotic and antimicrobial effects. This paper describes the use of cryopreserved amniotic membrane allografts to treat diabetic foot ulcers (DFUs) in patients with diabetes. METHOD: In this case series, AM was processed to obtain a final medicinal product: cryopreserved amniotic membrane. cryopreserved AM was applied every 7-10 days until total epithelialisation of the DFUs. RESULTS: A total of 14 patients with DFUs (median size: 12.30cm, (range: 0.52-42.5cm2) were treated and followed up until complete closure (median time: 20 weeks, range: 7-56 weeks). Patients received 4-40 AM applications. All patients in this study achieved complete epithelialisation of the wound. No adverse events were observed. CONCLUSION: AM is a feasible and safe treatment in complex DFUs. Furthermore, the treatment is successful in achieving epithelialisation of long-evolution, unhealed wounds resistant to conventional therapies.
OBJECTIVE: The amniotic membrane (AM) is a tissue with low immunogenity and high therapeutic potential due to its anti-inflammatory, anti-fibrotic and antimicrobial effects. This paper describes the use of cryopreserved amniotic membrane allografts to treat diabetic foot ulcers (DFUs) in patients with diabetes. METHOD: In this case series, AM was processed to obtain a final medicinal product: cryopreserved amniotic membrane. cryopreserved AM was applied every 7-10 days until total epithelialisation of the DFUs. RESULTS: A total of 14 patients with DFUs (median size: 12.30cm, (range: 0.52-42.5cm2) were treated and followed up until complete closure (median time: 20 weeks, range: 7-56 weeks). Patients received 4-40 AM applications. All patients in this study achieved complete epithelialisation of the wound. No adverse events were observed. CONCLUSION: AM is a feasible and safe treatment in complex DFUs. Furthermore, the treatment is successful in achieving epithelialisation of long-evolution, unhealed wounds resistant to conventional therapies.
Authors: Alzbeta Svobodova; Vojtech Horvath; Ingrida Smeringaiova; Joao Victor Cabral; Martina Zemlickova; Radovan Fiala; Jan Burkert; Denisa Nemetova; Petr Stadler; Jaroslav Lindner; Jan Bednar; Katerina Jirsova Journal: Int Wound J Date: 2021-11-17 Impact factor: 3.099
Authors: Caterina Pipino; Ángel Bernabé-García; Ilaria Cappellacci; Javier Stelling-Férez; Pamela Di Tomo; Manuela Santalucia; Carlos Navalón; Assunta Pandolfi; Francisco José Nicolás Journal: Front Bioeng Biotechnol Date: 2022-07-05